Should we change the treatment plan in early hepatocellular carcinoma with chronic kidney disease?

Abstract Background Chronic kidney disease (CKD) has been considered to be a poor prognostic factor for hepatocellular carcinoma (HCC). However, few studies have focused on early HCC and the impact of CKD on survival, which should be considered in curative treatment for early HCC. Materials and meth...

Full description

Bibliographic Details
Main Authors: Wu-Po Chao, Shion-Wei Chai, Po-Hsing Chiang, Ta-Chun Chou, Yi-Chan Chen, Ruey-Shyang Soong
Format: Article
Language:English
Published: BMC 2023-04-01
Series:BMC Surgery
Subjects:
Online Access:https://doi.org/10.1186/s12893-023-01983-y
_version_ 1827966484135018496
author Wu-Po Chao
Shion-Wei Chai
Po-Hsing Chiang
Ta-Chun Chou
Yi-Chan Chen
Ruey-Shyang Soong
author_facet Wu-Po Chao
Shion-Wei Chai
Po-Hsing Chiang
Ta-Chun Chou
Yi-Chan Chen
Ruey-Shyang Soong
author_sort Wu-Po Chao
collection DOAJ
description Abstract Background Chronic kidney disease (CKD) has been considered to be a poor prognostic factor for hepatocellular carcinoma (HCC). However, few studies have focused on early HCC and the impact of CKD on survival, which should be considered in curative treatment for early HCC. Materials and methods Patients with BCLC stage 0/A were enrolled from 2009 to 2019. A total of 383 patients were divided into Control group and CKD group, based on estimated glomerular filtration rate. Overall survival (OS) and disease-free survival (DFS) of different treatments were determined using the Kaplan–Meier method. Results The Control group had a significantly better OS than the CKD group (72.6 months vs. 56.7 months; p = 0.003). DFS was similar between the groups (62.2 months vs. 63.8 months, p = 0.717). In the Control group, the surgically treated (OP) group had significantly superior OS (65.0 months vs. 80.0 months, p = 0.014) and DFS (50.9 months vs. 70.2 months, p = 0.020) than the radiofrequency ablation-treated group. In the CKD group, the OP group showed a survival advantage in OS (70.6 months vs. 49.2 months, p = 0.004), while DFS was similar between treatment groups (56.0 months vs. 62.2 months, p = 0.097). Conclusion CKD should not be considered to be a poor prognostic factor in early HCC patients. Moreover, hepatectomy should be carried out in CKD patient with early HCC for better prognosis if feasible.
first_indexed 2024-04-09T17:50:44Z
format Article
id doaj.art-b9ffb73dc0064a85994051eb237d3c68
institution Directory Open Access Journal
issn 1471-2482
language English
last_indexed 2024-04-09T17:50:44Z
publishDate 2023-04-01
publisher BMC
record_format Article
series BMC Surgery
spelling doaj.art-b9ffb73dc0064a85994051eb237d3c682023-04-16T11:05:45ZengBMCBMC Surgery1471-24822023-04-012311810.1186/s12893-023-01983-yShould we change the treatment plan in early hepatocellular carcinoma with chronic kidney disease?Wu-Po Chao0Shion-Wei Chai1Po-Hsing Chiang2Ta-Chun Chou3Yi-Chan Chen4Ruey-Shyang Soong5Division of General Surgery, Department of Surgery, Keelung Chang Gung Memorial HospitalDivision of General Surgery, Department of Surgery, Keelung Chang Gung Memorial HospitalDivision of General Surgery, Department of Surgery, Keelung Chang Gung Memorial HospitalDivision of General Surgery, Department of Surgery, Keelung Chang Gung Memorial HospitalDivision of General Surgery, Department of Surgery, Keelung Chang Gung Memorial HospitalDivision of General Surgery, Department of Surgery, Wan Fang Hospital, Taipei Medical UniversityAbstract Background Chronic kidney disease (CKD) has been considered to be a poor prognostic factor for hepatocellular carcinoma (HCC). However, few studies have focused on early HCC and the impact of CKD on survival, which should be considered in curative treatment for early HCC. Materials and methods Patients with BCLC stage 0/A were enrolled from 2009 to 2019. A total of 383 patients were divided into Control group and CKD group, based on estimated glomerular filtration rate. Overall survival (OS) and disease-free survival (DFS) of different treatments were determined using the Kaplan–Meier method. Results The Control group had a significantly better OS than the CKD group (72.6 months vs. 56.7 months; p = 0.003). DFS was similar between the groups (62.2 months vs. 63.8 months, p = 0.717). In the Control group, the surgically treated (OP) group had significantly superior OS (65.0 months vs. 80.0 months, p = 0.014) and DFS (50.9 months vs. 70.2 months, p = 0.020) than the radiofrequency ablation-treated group. In the CKD group, the OP group showed a survival advantage in OS (70.6 months vs. 49.2 months, p = 0.004), while DFS was similar between treatment groups (56.0 months vs. 62.2 months, p = 0.097). Conclusion CKD should not be considered to be a poor prognostic factor in early HCC patients. Moreover, hepatectomy should be carried out in CKD patient with early HCC for better prognosis if feasible.https://doi.org/10.1186/s12893-023-01983-yhepatocellular carcinomachronic kidney diseasehepatectomyradiofrequency ablationsurvival
spellingShingle Wu-Po Chao
Shion-Wei Chai
Po-Hsing Chiang
Ta-Chun Chou
Yi-Chan Chen
Ruey-Shyang Soong
Should we change the treatment plan in early hepatocellular carcinoma with chronic kidney disease?
BMC Surgery
hepatocellular carcinoma
chronic kidney disease
hepatectomy
radiofrequency ablation
survival
title Should we change the treatment plan in early hepatocellular carcinoma with chronic kidney disease?
title_full Should we change the treatment plan in early hepatocellular carcinoma with chronic kidney disease?
title_fullStr Should we change the treatment plan in early hepatocellular carcinoma with chronic kidney disease?
title_full_unstemmed Should we change the treatment plan in early hepatocellular carcinoma with chronic kidney disease?
title_short Should we change the treatment plan in early hepatocellular carcinoma with chronic kidney disease?
title_sort should we change the treatment plan in early hepatocellular carcinoma with chronic kidney disease
topic hepatocellular carcinoma
chronic kidney disease
hepatectomy
radiofrequency ablation
survival
url https://doi.org/10.1186/s12893-023-01983-y
work_keys_str_mv AT wupochao shouldwechangethetreatmentplaninearlyhepatocellularcarcinomawithchronickidneydisease
AT shionweichai shouldwechangethetreatmentplaninearlyhepatocellularcarcinomawithchronickidneydisease
AT pohsingchiang shouldwechangethetreatmentplaninearlyhepatocellularcarcinomawithchronickidneydisease
AT tachunchou shouldwechangethetreatmentplaninearlyhepatocellularcarcinomawithchronickidneydisease
AT yichanchen shouldwechangethetreatmentplaninearlyhepatocellularcarcinomawithchronickidneydisease
AT rueyshyangsoong shouldwechangethetreatmentplaninearlyhepatocellularcarcinomawithchronickidneydisease